€35m · Growth/Late · Healthtech · Paris, France
Implicity, a Paris-based remote cardiac monitoring company, has raised €35m in growth equity led by IRIS alongside Five Arrows. The company's US-facing announcement describes the same financing as $40m.
The platform brings data from pacemakers, defibrillators, implantable cardiac monitors and heart-failure systems into one workflow, regardless of device manufacturer. It uses AI to prioritise alerts and can integrate with electronic health records, addressing a practical problem for cardiology teams that would otherwise review several vendor portals and growing volumes of device data.
Implicity says it now serves more than 250 medical centres and monitors over 120,000 patients each day across the US, France and Germany. The company also reports a 26% reduction in mortality and a 4% reduction in hospitalisations among patients monitored with its platform compared with conventional remote monitoring; those outcome figures are company claims tied to cited real-world research rather than results established by the financing announcement alone.
Proceeds will support commercial hiring and US-specific product features, continued European growth and further work on predictive and diagnostic AI, including the next generation of its heart-failure prediction tools.
The US expansion depends on fitting hospital operations
Implicity's commercial proposition is not simply that its algorithms can identify risk. Hospitals need a monitoring layer that connects multiple device makers, fits existing clinical and billing workflows, and reduces the number of alerts staff must investigate without hiding events that require action. That makes integration, regulatory clearance and evidence of clinical utility part of the product rather than supporting credentials.
The company has operated from Cambridge, Massachusetts since 2022 and already works with US medical centres. This round gives it capital to deepen that footprint with local hires and features, but the expansion test is whether more hospitals can adopt the platform without adding another disconnected system. A vendor-agnostic position becomes more valuable as a centre manages more device types, provided the software continues to preserve sensitivity while reducing review work.
Founded in 2016 by electrophysiologist Dr Arnaud Rosier, Implicity grew from his experience logging into separate manufacturer portals to monitor cardiac patients. MobiHealthNews reports that the company has secured FDA clearances for its SignalHF heart-failure risk tool and ILR ECG Analyzer. It previously announced a $23m Series A in 2022.
For IRIS and Five Arrows, the wager is that regulatory credibility, accumulated clinical evidence and workflow integration can turn a specialised monitoring product into infrastructure for larger health systems. The funding can accelerate distribution and product development; adoption will still depend on proving that those tools save scarce clinical time while maintaining dependable patient oversight.
